Harmony Biosciences announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug designation to pitolisant for the treatment of idiopathic hypersomnia, IH. Harmony is currently evaluating the efficacy and safety of pitolisant in adult patients with IH in the Phase 3 registrational INTUNE study, a double-blind, placebo-controlled, randomized withdrawal study. Topline study results are anticipated in the fourth quarter of 2023 following enrollment completion nine months ahead of plan. “The FDA’s decision to grant Orphan Drug designation reinforces our belief in pitolisant as a promising therapy for adult patients with IH, with the unique added benefit of it being a non-scheduled, once-daily treatment option working through histamine to improve wakefulness,” said Kumar Budur, M.D., Chief Medical Officer at Harmony Biosciences. “With the completion of enrollment in our INTUNE study nine months ahead of schedule and topline results expected in Q4, this designation is a significant advance in our clinical and commercial development initiatives. We look forward to working closely with the FDA and the broader IH community to address the unmet medical needs of patients living with this condition.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HRMY:
- Harmony Biosciences initiated with a Buy at Berenberg
- Harmony Biosciences receives FDA orphan drug designation for pitolisant
- Harmony Biosciences patent news ‘clear positive,’ says Mizuho
- Harmony Biosciences comments on ‘favorable’ decision by USPTO on WAKIX
- Biotech Alert: Searches spiking for these stocks today